Taku Okazaki

Immunology · 2000–2013

A researcher in the Science corpus: 10 papers; trusts 4 researchers and is trusted by 13 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 100 citations into it; #263 of 2,160 by trust here, #126 by citations
• Oncology — 68 citations into it; #146 of 1,698 by trust here, #92 by citations
• Molecular Biology — 14 citations into it
• Radiology, Nuclear Medicine and Imaging — 5 citations into it

Whom Taku Okazaki trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Ravetch
2. G. Freeman
3. R. Parry

Who trusts Taku Okazaki overall

1. James L. Riley
2. M. Keir
3. Arlene H. Sharpe
4. Lieping Chen
5. S. Topalian
6. B. Fife
7. D. Pardoll
8. G. Freeman
9. C. Blank
10. E. Wherry

Papers from Taku Okazaki's perspective

Ordered by how strongly the researchers Taku Okazaki trusts endorse each paper. Same corpus, a different order for every researcher.

1. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
2. B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells (Journal of Experimental Medicine)
3. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
4. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (Cancer Research)
5. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (Proceedings of the National Academy of Sciences of the United States of America)
6. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (Molecular and Cellular Biology)
7. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
8. PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion (Journal of Virology)
9. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. (New England Journal of Medicine)
10. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 (Journal of Immunology)

Their papers

• A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application (2013) — 877 citations
• PD-1 and PD-1 ligands: from discovery to clinical application. (2007) — 1,254 citations
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer (2007) — 1,381 citations
• The PD-1-PD-L pathway in immunological tolerance. (2006) — 744 citations
• Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice (2003) — 681 citations
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade (2002) — 3,014 citations
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine (2001) — 824 citations
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (2001) — 1,850 citations
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation (2001) — 2,945 citations
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (2000) — 5,135 citations